<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the numerous case series and emerging evidence with CP is compelling and well documented, it has several limitations as it is not evaluated in a randomized clinical trial, to determine the actual clinical benefit when compared to those who have not received it [
 <xref rid="R53" ref-type="bibr">53</xref>, 
 <xref rid="R58" ref-type="bibr">58</xref>]. In almost all the case series and studies published so far, the patients received numerous other therapies, including various antivirals, steroids, etc. It is also interesting to note that the timing of administration of the CP was different in multiple studies. Prior studies have shown that passive antibody therapy is most effective if given prophylactically or used early in the disease course.
</p>
